282
Participants
Start Date
August 5, 2014
Primary Completion Date
May 9, 2017
Study Completion Date
September 1, 2017
onabotulinumtoxinA
155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks.
Topiramate
Topiramate up to a maximum oral dose of 100 mg/day.
Montefiore Headache Center, The Bronx
Island Neurological Associates PC, Plainview
Dent Neurosciences Research Center Incorporated, Amherst
Preferred Primary Care Physicians, Pittsburgh
Main Line Health Lankenau Hospital, Wynnewood
Thomas Jefferson University, Philadelphia
Headache Wellness Center, Greensboro
Raleigh Neurology Associates PA, Raleigh
Asheville Neurology Specialists PA, Asheville
NW FL Clinical Research Group, LLC, Gulf Breeze
Design Neuroscience Center, Doral
Neurology Research Institute at Palm Beach Neurology, West Palm Beach
Parkinson's Disease and Movement Disorders Center of Boca Raton Inc, Boca Raton
Negroski, Sutherland & Hanes Neurology, Sarasota
Allegiance Health, Jackson
Robbins Headache Clinic, Riverwoods
Mercy Health Research, St Louis
Clinvest, Springfield
International Clinical Research Institute Inc, Overland Park
Kansas City Bone and Joint Clinic, Overland Park
The NeuroMedical Center, Baton Rouge
Texas Neurology, Dallas
Denver Neurological Clinic, Denver
St Joseph's Hospital Barrow Neurology Clinics, Phoenix
Renown Institute for Neurosciences, Reno
North County Neurology Associates, Encinitas
Newport Beach Clinical Research Associates, Inc., Newport Beach
California Headache and Balance Center, Fresno
Puget Sound Neurology, Tacoma
Ki Health Partners LLC DBA New England Institute for Neurology and Headache, Stamford
MedVadis Research Corporation, Watertown
New England Regional Headache Center Inc, Worcester
Lead Sponsor
Allergan
INDUSTRY